Silence Therapeutics PLC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
A filing reveals that Invus Public Equities, L.P. and affiliated entities now collectively beneficially own 7.0% of Silence Therapeutics plc's ordinary shares.
NASDAQ
Lombard Odier Asset Management (USA) Corp reported a 4.2% beneficial ownership stake in Silence Therapeutics plc as of December 31, 2025.
NASDAQ
SCHEDULE 13G/A: Redmile Group and Jeremy C. Green Disclose 4.7% Passive Stake in Silence Therapeutics plc
Redmile Group, LLC and its principal, Jeremy C. Green, have reported a combined beneficial ownership of 4.7% of Silence Therapeutics plc's Ordinary Shares, held through private investment vehicles.
NASDAQ
Investment firm Redmile Group, LLC and its principal Jeremy C. Green have disclosed a beneficial ownership of 5.1% in Silence Therapeutics plc, holding over 7.1 million ordinary shares as of December 31, 2024.
NASDAQ
Lombard Odier Asset Management (USA) Corp has filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% in Silence Therapeutics plc as of December 31, 2024.